Aegon (AGN) AGM 2026 summary

Opening remarks and agenda

• AGM convened in Bermuda on June 10, 2026, covering the 2025 accounts and business review, remuneration, dividend, Board composition, share authorities, and other business.

• Voting and virtual participation procedures were explained, with live voting and Q&A through Lumi; meeting compliance with Bermuda, Dutch, and U.S. requirements was confirmed.

Financial performance review

• FY25 financial targets set at CMD 2023 were delivered or exceeded; operating result rose to €1.7bn, with growth across business units.

• Operating capital generation was €1,287m before holding funding and operating expenses; free cash flow was €829m, both ahead of targets.

• Returned over €500m through share buybacks and ~€600m in dividends during 2025; dividend per share grew by double digits to €0.40, with group leverage at €5bn.

• Sale of the UK business to Standard Life for £750m plus shares valued at £2bn.

Strategic initiatives and plans

• Strategic focus sharpened on building a leading U.S. life insurance and retirement group, targeting the large and growing U.S. market.

• Legal domicile, group regulator, and domestic issuer status targeted to transition on Jan. 1, 2028; milestones may be deferred if needed, with a planned name change to Transamerica Inc.

• U.S. GAAP transition includes FY27 reporting in February 2028 and 1Q28 reporting in May 2028; operational shift from Amsterdam to the U.S. planned.

• EGM in Q4 2026 to consider redomiciliation, constitutional amendments for a U.S.-aligned governance framework, and a new omnibus share plan; shareholder engagement planned ahead of the vote.

• Dual Euronext and NYSE listings to continue, with future inclusion in U.S.-focused indices targeted.